ELTX
Elicio Therapeutics, Inc.Healthcare · $35M market cap
Verdict
We can't put a fair value on ELTX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow ELTX
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Aug 31, 2026: no open-market purchases and 7 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
Venkatesan Jay
director · 2026-08-31
Award
$59K
WILSON KAREN J
director · 2026-08-31
Award
$59K
RUFFOLO ROBERT R
director · 2026-08-31
Award
$59K
Nissenson Allen
director · 2026-08-31
Award
$59K
Chudnovsky Yekaterina
director · 2026-08-31
Award
$59K
Show all 7 other filingsShow fewer
Ashe Carol Gail
director · 2026-08-31
Award
$59K
ADAMS JULIAN
director · 2026-08-31
Award
$59K
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works